PBPatricia V. Basta

Patricia V. Basta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Patricia V. Basta has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Table 1 from The University of North Carolina Cancer Survivorship Cohort: A Resource for Collaborative Survivorship Research

    by Chelsea Anderson, Jeannette T. Bensen, Emma H. Allott, Patricia V. Basta, Debra E. Irwin, Adrian Gerstel, Laura Farnan, Hung-Jui Tan, Erin E. Kent, Tzy-Mey Kuo, et al.

    Supplemental Table 1. UNC Cancer Survivorship Cohort cancer-specific questionnaires

  • Open Access

    Data from The University of North Carolina Cancer Survivorship Cohort: A Resource for Collaborative Survivorship Research

    by Chelsea Anderson, Jeannette T. Bensen, Emma H. Allott, Patricia V. Basta, Debra E. Irwin, Adrian Gerstel, Laura Farnan, Hung-Jui Tan, Erin E. Kent, Tzy-Mey Kuo, et al.

    Background:Rapid growth in the number of US cancer survivors drives the need for ongoing research efforts to improve outcomes and experiences after cancer. In this study, we describe the University of North Carolina (UNC) Cancer Survivorship Cohort, a medical center–based cohort of adults with cancer that integrates medical record–abstracted cancer information, patient-reported outcomes, and biological specimens.Methods:Participants ages 18+ were recruited from UNC oncology clinics between April 2010 and August 2016. After enrollment, participants completed questionnaires on a range of topics including demographics, health history, healthcare access and utilization, quality of life, and symptoms. Blood samples and tumor tissue specimens were collected and processed by study staff, and cancer characteristics and other clinical data were abstracted from electronic medical records. Participants consented to recontact for future studies and linkage of their data with other data resources.Results:In total, 3,999 participants with a cancer diagnosis were enrolled in the cohort. The most common cancer types among those enrolled included breast (N = 866), uterine (N = 458), colorectal (N = 300), prostate (N = 296), and head and neck (N = 248) cancers. Blood specimens were collected for 3,027 participants (76%). Additional participants without cancer (N = 1,299) were also enrolled, and the majority (62%) provided biospecimen samples.Conclusions:We encourage a wide collaboration with investigators across institutions seeking to advance research in cancer survivorship. Procedures are in place to support proposals for use of existing or linked data and for proposals that require participant recontact or analysis of biospecimens.Impact:The UNC Cancer Survivorship Cohort is a unique resource for cancer survivorship research.

  • The University of North Carolina Cancer Survivorship Cohort: A Resource for Collaborative Survivorship Research

    by Chelsea Anderson, Jeannette T. Bensen, Emma H. Allott, Patricia V. Basta, Debra E. Irwin, Adrian Gerstel, Laura Farnan, Hung-Jui Tan, Erin E. Kent, Tzy-Mey Kuo, et al.

    Background: Rapid growth in the number of US cancer survivors drives the need for ongoing research efforts to improve outcomes and experiences after cancer. In this study, we describe the University of North Carolina (UNC) Cancer Survivorship Cohort, a medical center–based cohort of adults with cancer that integrates medical record–abstracted cancer information, patient-reported outcomes, and biological specimens. Methods: Participants ages 18+ were recruited from UNC oncology clinics between April 2010 and August 2016. After enrollment, participants completed questionnaires on a range of topics including demographics, health history, healthcare access and utilization, quality of life, and symptoms. Blood samples and tumor tissue specimens were collected and processed by study staff, and cancer characteristics and other clinical data were abstracted from electronic medical records. Participants consented to recontact for future studies and linkage of their data with other data resources. Results: In total, 3,999 participants with a cancer diagnosis were enrolled in the cohort. The most common cancer types among those enrolled included breast (N = 866), uterine (N = 458), colorectal (N = 300), prostate (N = 296), and head and neck (N = 248) cancers. Blood specimens were collected for 3,027 participants (76%). Additional participants without cancer (N = 1,299) were also enrolled, and the majority (62%) provided biospecimen samples. Conclusions: We encourage a wide collaboration with investigators across institutions seeking to advance research in cancer survivorship. Procedures are in place to support proposals for use of existing or linked data and for proposals that require participant recontact or analysis of biospecimens. Impact: The UNC Cancer Survivorship Cohort is a unique resource for cancer survivorship research.


  • Open Access

    Common Genetic Polymorphisms Influence Blood Biomarker Measurements in COPD

    by Wei Sun, Katerina Kechris, Sean Jacobson, M. Bradley Drummond, Gregory A. Hawkins, Jenny Yang, Ting-Huei Chen, Pedro Miguel Quibrera, Wayne Anderson, R. Graham Barr, et al.

    Implementing precision medicine for complex diseases such as chronic obstructive lung disease (COPD) will require extensive use of biomarkers and an in-depth understanding of how genetic, epigenetic, and environmental variations contribute to phenotypic diversity and disease progression. A meta-analysis from two large cohorts of current and former smokers with and without COPD [SPIROMICS (N = 750); COPDGene (N = 590)] was used to identify single nucleotide polymorphisms (SNPs) associated with measurement of 88 blood proteins (protein quantitative trait loci; pQTLs). PQTLs consistently replicated between the two cohorts. Features of pQTLs were compared to previously reported expression QTLs (eQTLs). Inference of causal relations of pQTL genotypes, biomarker measurements, and four clinical COPD phenotypes (airflow obstruction, emphysema, exacerbation history, and chronic bronchitis) were explored using conditional independence tests. We identified 527 highly significant (p < 8 X 10−10) pQTLs in 38 (43%) of blood proteins tested. Most pQTL SNPs were novel with low overlap to eQTL SNPs. The pQTL SNPs explained >10% of measured variation in 13 protein biomarkers, with a single SNP (rs7041; p = 10−392) explaining 71%-75% of the measured variation in vitamin D binding protein (gene = GC). Some of these pQTLs [e.g., pQTLs for VDBP, sRAGE (gene = AGER), surfactant protein D (gene = SFTPD), and TNFRSF10C] have been previously associated with COPD phenotypes. Most pQTLs were local (cis), but distant (trans) pQTL SNPs in the ABO blood group locus were the top pQTL SNPs for five proteins. The inclusion of pQTL SNPs improved the clinical predictive value for the established association of sRAGE and emphysema, and the explanation of variance (R2) for emphysema improved from 0.3 to 0.4 when the pQTL SNP was included in the model along with clinical covariates. Causal modeling provided insight into specific pQTL-disease relationships for airflow obstruction and emphysema. In conclusion, given the frequency of highly significant local pQTLs, the large amount of variance potentially explained by pQTL, and the differences observed between pQTLs and eQTLs SNPs, we recommend that protein biomarker-disease association studies take into account the potential effect of common local SNPs and that pQTLs be integrated along with eQTLs to uncover disease mechanisms. Large-scale blood biomarker studies would also benefit from close attention to the ABO blood group. Precision medicine is an emerging approach that takes into account variability in genes, gene and protein expression, environment and lifestyle. Recent advances in high-throughput genome-wide genotyping, genomics, and proteomics coupled with the creation of large, highly-phenotyped clinical cohorts now allows for integration of these molecular data sets at the individual level. Here we use genome-wide genotyping and blood measurements of 88 biomarkers in 1,340 subjects from two large NIH-supported clinical cohorts of smokers (SPIROMICS and COPDGene) to identify more than 300 novel DNA variants that influence measurement of blood protein levels (pQTLs). We find that many DNA variants explain a large portion of the variability of measured protein expression in blood. Furthermore, we show that integration of DNA variants with blood biomarker levels can improve the ability of predictive models to reflect the relationship between biomarker and disease features (e.g., emphysema) within chronic obstructive pulmonary disease (COPD).


  • Open Access

    Collecting Biospecimens From an Internet-Based Prospective Cohort Study of Inflammatory Bowel Disease (CCFA Partners): A Feasibility Study

    by Rachel L Randell, Ajay S Gulati, Suzanne F Cook, Christopher F Martin, Wenli Chen, Elizabeth L Jaeger, Alexi A Schoenborn, Patricia V Basta, Hendrik Dejong, Jingchun Luo, et al.

    The Internet has successfully been used for patient-oriented survey research. Internet-based translational research may also be possible. Our aim was to study the feasibility of collecting biospecimens from CCFA Partners, an Internet-based inflammatory bowel disease (IBD) cohort. From August 20, 2013, to January 4, 2014, we randomly sampled 412 participants, plus 179 from a prior validation study, and invited them to contribute a biospecimen. Participants were randomized to type (blood, saliva), incentive (none, US $20, or US $50), and collection method for blood. The first 82 contributors were also invited to contribute stool. We used descriptive statistics and t tests for comparisons. Of the 591 participants, 239 (40.4%) indicated interest and 171 (28.9%) contributed a biospecimen. Validation study participants were more likely to contribute than randomly selected participants (44% versus 23%, P<.001). The return rate for saliva was higher than blood collected by mobile phlebotomist and at doctors' offices (38%, 31%, and 17% respectively, P<.001). For saliva, incentives were associated with higher return rates (43-44% versus 26%, P=.04); 61% contributed stool. Fourteen IBD-associated single nucleotide polymorphisms were genotyped, and risk allele frequencies were comparable to other large IBD populations. Bacterial DNA was successfully extracted from stool samples and was of sufficient quality to permit quantitative polymerase chain reaction for total bacteria. Participants are willing to contribute and it is feasible to collect biospecimens from an Internet-based IBD cohort. Home saliva kits yielded the highest return rate, though mobile phlebotomy was also effective. All samples were sufficient for genetic testing. These data support the feasibility of developing a centralized collection of biospecimens from this cohort to facilitate IBD translational studies.